DK2812011T3 - Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler - Google Patents

Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler Download PDF

Info

Publication number
DK2812011T3
DK2812011T3 DK13709575.8T DK13709575T DK2812011T3 DK 2812011 T3 DK2812011 T3 DK 2812011T3 DK 13709575 T DK13709575 T DK 13709575T DK 2812011 T3 DK2812011 T3 DK 2812011T3
Authority
DK
Denmark
Prior art keywords
cells
differentizing
vivo
hematopoietic
hematopoietic cells
Prior art date
Application number
DK13709575.8T
Other languages
English (en)
Inventor
Jan Spanholtz
Harmen Dolstra
Original Assignee
Glycostem Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycostem Therapeutics B V filed Critical Glycostem Therapeutics B V
Application granted granted Critical
Publication of DK2812011T3 publication Critical patent/DK2812011T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
DK13709575.8T 2012-02-08 2013-02-07 Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler DK2812011T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12154554 2012-02-08
PCT/NL2013/050073 WO2013119118A1 (en) 2012-02-08 2013-02-07 Ex vivo nk cell differentiation from cd34+ hematopoietic cells

Publications (1)

Publication Number Publication Date
DK2812011T3 true DK2812011T3 (da) 2020-02-24

Family

ID=47884461

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13709575.8T DK2812011T3 (da) 2012-02-08 2013-02-07 Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler

Country Status (7)

Country Link
US (3) US20150010583A1 (da)
EP (1) EP2812011B1 (da)
CA (1) CA2864283C (da)
DK (1) DK2812011T3 (da)
ES (1) ES2771248T3 (da)
PL (1) PL2812011T3 (da)
WO (1) WO2013119118A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017014269A2 (pt) * 2014-12-31 2018-03-27 Anthrogenesis Corp células exterminadoras naturais e usos das mesmas
WO2017042393A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
EP3350316B1 (en) * 2015-09-15 2024-05-08 Stichting Radboud universitair medisch centrum IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST
EA201890960A1 (ru) * 2015-10-15 2018-10-31 Селулэрити, Инк. Натуральные киллеры и клетки ilc3 и их применение
SI3405495T1 (sl) * 2016-01-21 2021-08-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih
BR112018072701A2 (pt) 2016-05-07 2019-02-19 Celularity, Inc. métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais
IT201600121081A1 (it) * 2016-11-29 2018-05-29 Fond Ri Med Immunoterapia NK-mediata e usi di essa
JP6647240B2 (ja) * 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd A method for the production of natural killer cells and a preparation for cancer treatment
CN108315299A (zh) * 2018-02-13 2018-07-24 南京支云松生物科技有限公司 一种即用型异体nk细胞库网络储运应用系统
KR20210016567A (ko) * 2018-05-30 2021-02-16 글리코스템 떼라퓨틱스 비.브이. Car nk 세포
WO2020124256A1 (en) * 2018-12-21 2020-06-25 Stemcell Technologies Canada Inc. Media and methods for differentiating natural killer cells
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
AU2019456283B2 (en) 2019-07-08 2023-06-08 Immunitybio, Inc. Mononuclear cell derived NK cells
CN114402065A (zh) * 2019-07-22 2022-04-26 格雷克斯迪姆医疗私人有限公司 低密度细胞培养
WO2021107779A1 (en) * 2019-11-28 2021-06-03 Glycostem Therapeutics B.V. Method for obtaining car-nk cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN113416700B (zh) * 2021-07-09 2023-04-11 天晴干细胞股份有限公司 一种高效的因子分泌型nk细胞扩增方法及其应用
KR102504039B1 (ko) * 2022-10-25 2023-03-02 오정훈 자연살해세포 증식에 효과적인 배양 방법 및 이의 용도
WO2026005479A1 (ko) * 2024-06-25 2026-01-02 주식회사 온코인사이트 자연살해세포 및 car-nk 세포의 제조 방법, 이에 따라 제조된 자연살해세포 및 car-nk 세포, 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297471A1 (en) * 2004-05-28 2009-12-03 Mayo Foundation For Medical Education And Research Methods For Autologous Stem Cell Transplantation
WO2006102209A2 (en) * 2005-03-18 2006-09-28 The Ohio State University Research Foundation Cd34(+) cells and their methods of use
PL1941027T3 (pl) * 2005-09-28 2015-01-30 Ipd Therapeutics B V Metody i środki do proliferacji komórek macierzystych oraz wytwarzania i ekspansji komórek progenitorowych, a także produkcji komórek efektorowych jako leków klinicznych
US9193953B2 (en) * 2007-03-27 2015-11-24 Ipd-Therapeutics B.V. Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells

Also Published As

Publication number Publication date
US20180044636A1 (en) 2018-02-15
EP2812011B1 (en) 2020-01-15
US10822589B2 (en) 2020-11-03
US20150010583A1 (en) 2015-01-08
US20210054338A1 (en) 2021-02-25
PL2812011T3 (pl) 2020-06-29
CA2864283A1 (en) 2013-08-15
ES2771248T3 (es) 2020-07-06
EP2812011A1 (en) 2014-12-17
CA2864283C (en) 2020-11-03
WO2013119118A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
DK2812011T3 (da) Differentiering ex vivo af nk-celler fra cd34+ hæmatopoietiske celler
SMT201500263B (it) Composizioni solide
DK3725778T4 (da) Formuleringer af enzalutamid
FR2950069B1 (fr) Utilisation de compositions ternaires
DK2640893T4 (da) Sammensætninger
PT2593094T (pt) Composição aquosa contendo bromexina
EP2758441A4 (en) MODIFIED POLYETHYLENE COMPOSITIONS
LT3246021T (lt) Apiksabano kompozicijos
PT3023788T (pt) Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
EP2713762A4 (en) Stevia-COMPOSITION
EP2743306A4 (en) NETWORKED POLYETHYLENE COMPOSITION
EP2758183A4 (en) BIODEGRADABLE COMPOSITIONS AND THEIR USE
DK2911506T3 (da) Driftreducerende sammensætninger
CO6930368A2 (es) Composiciones de yodo-povidona estable
PT2852389T (pt) Composições que compreendem benzodiazepinas de ação rápida
CO6980141A1 (es) Compuestos y composiciones de poliglicerilo catónicos
DK2633006T3 (da) Fremstilling af fornybart bio-destillat
DK2822568T3 (da) Anvendelser af caseinsammensætninger
EP2652115A4 (en) Fluoropolymer COMPOSITION
ME03413B (me) Kompozicije које sadrže peg i askorbat
EP2559720A4 (en) NETWORKED COMPOSITION
EP2635269A4 (en) COMBINATION COMPOSITION
EP2825610A4 (en) STABILIZED IODOCALINE COMPOSITIONS